Taige International Securities Evaluates Biotech Gains Driving 2025 Momentum

CORNELIUS, N.C. - June 17, 2025 - PRLog -- Taige International Securities, a leading Asia-Pacific investment advisory firm, today published its mid-year report assessing the robust momentum in the global biotechnology sector. The firm highlights key themes positioning biotech at the forefront of strategic investment in 2025.

Cross-Border Licensing & Strategic Deals

2025 has seen a surge in licensing activity between U.S. and Chinese life sciences firms. In H1 alone, U.S. pharma giants executed 14 licensing agreements worth $18.3 billion with Chinese biotech companies—up dramatically from just two in the same period a year prior.

Deals include Pfizer's $1.25 billion upfront to 3SBio and Regeneron's $80 million pact with Hansoh Pharmaceuticals—signaling a broader strategic shift towards cost-effective, innovation-led development.

Mega M&A and Gene-Editing Expansion

In addition, the industry is seeing transactions that establish new records. Eli Lilly is in the process of acquiring Verve Therapeutics, a pioneer in gene editing, for a price of $1.3 billion, which includes an upfront payment of about $1 billion. This acquisition would strengthen Eli Lilly's metabolic and cardiovascular portfolio.

Furthermore, AstraZeneca has initiated a research agreement with CSPC in China, which is estimated to be worth up to $5 billion. This agreement reflects the increased faith that the company has in AI-driven pre-clinical drug development.

China's Advancement in Biotechnology

The United States has now surpassed by China in terms of the amount of worldwide biotech clinical trial activity that it produces. In 2024, China accounted for one-third of licensing molecules, which is a significant increase from the almost nonexistent amount in 2019.

Private Funding & Late-Stage Focus

The funding landscape in 2025 is shaped by cautious capital—but with a tilt toward fewer, larger deals targeting late-stage development. More than 75% of biotech VC in Q1 went into megarounds exceeding $100 million, supporting companies with clinical-stage assets and advanced commercialization prospects.

Taige International Securities

Taige International Securities believe it is essential to deliver insightful advice on an objective basis in order to properly serve our clients. We strive to educate our clients to allow for a more informed decision making process. We pride ourselves on presenting a bespoke service which allows for a more proactive and innovative approach to money management. Our ability to react to positive and adverse market conditions is second to none. You may also contact us at https://taigeintsec.com for further information.

Michelle Parker
PR Director
+85252313466
info@taigeintsec.com
27 Queen's Road East, Hong Kong Island, Hong Kong